Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.

MLA

Richardson, Debra L., et al. “Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate, in Combination with Carboplatin and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer.” Gynecologic Oncology, vol. 185, June 2024, pp. 186–93. EBSCOhost, https://doi.org/10.1016/j.ygyno.2024.01.045.

APA

Richardson, D. L., Moore, K. N., Vergote, I., Gilbert, L., Martin, L. P., Mantia-Smaldone, G. M., Castro, C. M., Provencher, D., Matulonis, U. A., Stec, J., Wang, Y., Method, M., & O’Malley, D. M. (2024). Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecologic Oncology, 185, 186–193. https://doi.org/10.1016/j.ygyno.2024.01.045

Chicago

Richardson, Debra L, Kathleen N Moore, Ignace Vergote, Lucy Gilbert, Lainie P Martin, Gina M Mantia-Smaldone, Cesar M Castro, et al. 2024. “Phase 1b Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate, in Combination with Carboplatin and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer.” Gynecologic Oncology 185 (June): 186–93. doi:10.1016/j.ygyno.2024.01.045.